Registry-listed formulations

chloroquine diphosphate · mesh:C023676

Each study is counted once in the molecule profile. Registry products remain separate. Naming an ingredient does not establish that products are interchangeable or what participants received.

10 source entries across 10 studies. This list may not include all unresolved or historical entries.

  • chloroquine phosphateRegistry intervention

    Linked study entry; product equivalence not established

    View study and source
  • chloroquine phosphate 1000 mgRegistry intervention

    Linked study entry; product equivalence not established

    View study and source
  • Chloroquine diphosphate 250mgRegistry intervention

    Linked study entry; product equivalence not established

    View study and source
  • Chloroquine phosphateRegistry intervention

    Linked study entry; product equivalence not established

    View study and source
  • Chloroquine PhosphateRegistry intervention

    Linked study entry; product equivalence not established

    View study and source
  • Chloroquine PhosphateRegistry intervention

    Linked study entry; product equivalence not established

    View study and source
  • Chloroquine PhosphateRegistry intervention

    Linked study entry; product equivalence not established

    View study and source
  • Chloroquine phosphateRegistry intervention

    Linked study entry; product equivalence not established

    View study and source
  • Chloroquine phosphateRegistry intervention

    Linked study entry; product equivalence not established

    View study and source
  • Chloroquine PhosphateRegistry intervention

    Linked study entry; product equivalence not established

    View study and source

Success Metrics

Clinical Success Rate
100.0%

Based on 10 completed trials

Completion Rate
83%(10/12)
Active Trials
1(7%)
Results Posted
40%(4 trials)
Terminated
2(14%)

Phase Distribution

Phase 1/2
1
7%
Phase 2/3
1
7%
Phase 4
4
29%
Not Applicable
1
7%
Phase 2
3
21%
Phase 1
4
29%

Phase Distribution

4

Early Stage

5

Mid Stage

4

Late Stage

Phase Distribution14 total trials
Phase 1Safety & dosage
4(28.6%)
Phase 1/2Combined phases
1(7.1%)
Phase 2Efficacy & side effects
3(21.4%)
Phase 2/3Combined phases
1(7.1%)
Phase 4Post-market surveillance
4(28.6%)
N/ANon-phased studies
1(7.1%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

83.3%

10 of 12 finished

Non-Completion Rate

16.7%

2 ended early

Currently Active

1

trials recruiting

Total Trials

14

all time

Status Distribution
Active(1)
Completed(10)
Terminated(2)
Other(1)

Detailed Status

Completed10
Terminated2
Recruiting1
unknown1

Development Timeline

Analytics

Development Status

Total Trials
14
Active
1
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 14 (28.6%)
Phase 1/21 (7.1%)
Phase 23 (21.4%)
Phase 2/31 (7.1%)
Phase 44 (28.6%)
N/A1 (7.1%)

Trials by Status

completed1071%
recruiting17%
unknown17%
terminated214%

Recent Activity

1 active trials
Showing 5 of 14
terminatedphase_1

The Seven Trial: Exploiting the Unfolded Protein Response

NCT06076837
completedphase_1_2

Sanaria PfSPZ Challenge With Pyrimethamine or Chloroquine Chemoprophylaxis Vaccination (PfSPZ-CVac Approach): A Randomized Double Blind Placebo Controlled Phase I/II Trial to Determine Safety and Protective Efficacy Against Natural Plasmodium Falcipa...

NCT03952650
completedphase_2

Chloroquine Diphosphate for the Treatment of Severe Acute Respiratory Syndrome Secondary to SARS-CoV2

NCT04323527
completedphase_2

Chloroquine Diphosphate in the Prevention of SARS in Covid-19 Infection

NCT04342650
completedphase_1

Dose Escalation PfSPZ-CVac

NCT03083847
View all 14 trials

Clinical Trials (14)

Showing 14 of 14 trials
NCT06076837Phase 1

The Seven Trial: Exploiting the Unfolded Protein Response

Terminated
NCT03952650Phase 1/2

Sanaria PfSPZ Challenge With Pyrimethamine or Chloroquine Chemoprophylaxis Vaccination (PfSPZ-CVac Approach): A Randomized Double Blind Placebo Controlled Phase I/II Trial to Determine Safety and Protective Efficacy Against Natural Plasmodium Falcipa...

Completed
NCT04323527Phase 2

Chloroquine Diphosphate for the Treatment of Severe Acute Respiratory Syndrome Secondary to SARS-CoV2

Completed
NCT04342650Phase 2

Chloroquine Diphosphate in the Prevention of SARS in Covid-19 Infection

Completed
NCT03083847Phase 1

Dose Escalation PfSPZ-CVac

Completed
NCT04331600Phase 4

Chloroquine as Antiviral Treatment in Coronavirus Infection 2020

Completed
NCT04443270Phase 1

Chloroquine Phosphate Prophylactic Use in Health Personnel Exposed to COVID-19 Patients

Unknown
NCT00308620Phase 2/3

Investigating the Anti-Human Immunodeficiency Virus (HIV) & Anti-inflammatory Effect of Chloroquine

Terminated
NCT02932007Phase 2

Chloroquine for Patients With Symptomatic Persistent Atrial Fibrillation: A Prospective Pilot Study

Recruiting
NCT02463331Phase 4

Possible Role of Chloroquine to Induce a Complete Remission in the Treatment of Autoimmune Hepatitis: a Randomized Trial

Completed
NCT01980745Phase 4

CHLOROQUINE FOR MAINTENANCE REMISSION OF AUTOIMMUNE HEPATITIS

Completed
NCT01727531Not Applicable

IDO2 Genetic Status Informs the Neoadjuvant Efficacy of Chloroquine (CQ) in Brain Metastasis Radiotherapy

Completed
NCT02394197Phase 4

Effectiveness of Malaria Treatment in Mexico

Completed
NCT01366235Phase 1

Clinical Trial for Evaluation of Ethnic Differences in Pharmacokinetics of Chloroquine, an Anti-malarial Drug

Completed

All 14 trials loaded

Drug Details

Intervention Type
Drug
Total Trials
14

Names & Codes

Trade Names

Resochin